Table of Contents
Highlights from the Literature
Priority Brief
- Priority BriefXiuli Zhang, Samuel Kim, Jasreet Hundal, John M. Herndon, Shunqiang Li, Allegra A. Petti, Savas D. Soysal, Lijin Li, Mike D. McLellan, Jeremy Hoog, Tina Primeau, Nancy Myers, Tammi L. Vickery, Mark Sturmoski, Ian S. Hagemann, Chris A. Miller, Matthew J. Ellis, Elaine R. Mardis, Ted Hansen, Timothy P. Fleming, S. Peter Goedegebuure and William E. GillandersCancer Immunol Res July 1 2017 5 (7) 516-523; DOI:10.1158/2326-6066.CIR-16-0264
Neoantigens are valuable for immunotherapy, but human breast cancers offer fewer than other cancers. With next-generation sequencing and computerized epitope-prediction, neoantigens in breast cancer were identified. The immune system recognized these neoantigens and protected mice from tumor challenge.
Research Articles
- Research ArticlesTi Wen, Zhenning Wang, Yi Li, Zhi Li, Xiaofang Che, Yibo Fan, Shuo Wang, Jinglei Qu, Xianghong Yang, Kezuo Hou, Wenyang Zhou, Ling Xu, Ce Li, Jin Wang, Jing Liu, Liqun Chen, Jingdong Zhang, Xiujuan Qu and Yunpeng LiuCancer Immunol Res July 1 2017 5 (7) 524-534; DOI:10.1158/2326-6066.CIR-16-0381
The American Joint Committee on Cancer (AJCC) staging system for gastric cancer is insufficiently prognostic. An immunoscore system based on PD-L1 expression on tumor or immune cells, PD-1 expression, and infiltration of CD8+ T cells was more prognostic and complements the AJCC system.
- Research ArticlesFloris Dammeijer, Lysanne A. Lievense, Margaretha E. Kaijen-Lambers, Menno van Nimwegen, Koen Bezemer, Joost P. Hegmans, Thorbald van Hall, Rudi W. Hendriks and Joachim G. AertsCancer Immunol Res July 1 2017 5 (7) 535-546; DOI:10.1158/2326-6066.CIR-16-0309
Mesothelioma has a poor prognosis and resists conventional therapies. Although tumor-associated macrophage depletion alone cannot restore antitumor immunity, its combination with dendritic cell–based therapy enhanced immune activation and survival in mesothelioma tumor models.
- Research ArticlesQian Zhou, Miao Xian, Senfeng Xiang, Danyan Xiang, Xuejing Shao, Jincheng Wang, Ji Cao, Xiaochun Yang, Bo Yang, Meidan Ying and Qiaojun HeCancer Immunol Res July 1 2017 5 (7) 547-559; DOI:10.1158/2326-6066.CIR-16-0259
Metastasis of osteosarcoma to lung depends on tumor-associated macrophages. All-trans retinoic acid (ATRA) inhibited this metastasis in mice. ATRA downregulated secretion of MMP12, a macrophage-secreted elastase. The results identify ATRA as a possible antimetastasis therapeutic.
- Research ArticlesJing Liao, Yan Luan, Zhenhua Ren, Xiaojuan Liu, Diyuan Xue, Hairong Xu, Zhichen Sun, Kaiting Yang, Hua Peng and Yang-Xin FuCancer Immunol Res July 1 2017 5 (7) 560-570; DOI:10.1158/2326-6066.CIR-16-0221
Although mAbs to hCD20 are used therapeutically for B-cell lymphoma, some lymphomas are resistant. In mice, interferon-α (IFNα) abolished resistance. Treatment with an anti-CD20–IFNα fusion protein eradicated B-cell lymphoma by co-opting tumor cells to present antigen.
- Research ArticlesGiedre Krenciute, Brooke L. Prinzing, Zhongzhen Yi, Meng-Fen Wu, Hao Liu, Gianpietro Dotti, Irina V. Balyasnikova and Stephen GottschalkCancer Immunol Res July 1 2017 5 (7) 571-581; DOI:10.1158/2326-6066.CIR-16-0376
Glioblastoma responds imperfectly to immunotherapy. Transgenic expression of IL15 in T cells expressing chimeric antigen receptors improved their proliferative capacity, persistence, and cytokine production. The emergence of antigen-loss variants highlights the need to target multiple tumor antigens.
- Research ArticlesAlexandra Frazao, Marina Colombo, Emmanuelle Fourmentraux-Neves, Meriem Messaoudene, Sylvie Rusakiewicz, Laurence Zitvogel, Eric Vivier, Frédéric Vély, Florence Faure, Brigitte Dréno, Houssem Benlalam, Fanny Bouquet, Ariel Savina, Eric Pasmant, Antoine Toubert, Marie-Françoise Avril and Anne CaignardCancer Immunol Res July 1 2017 5 (7) 582-593; DOI:10.1158/2326-6066.CIR-16-0380
Vemurafenib-treated melanomas of most patients whose tumors harbor BRAF mutations regress, but not durably. Vemurafenib, a Raf kinase-inhibitor, was found to alter expression of natural killer cell–recognized stress-induced ligands, which in turn affected natural killer cell cytotoxicity.
- Research ArticlesMax Kates, Thomas Nirschl, Nikolai A. Sopko, Hotaka Matsui, Christina M. Kochel, Leonardo O. Reis, George J. Netto, Mohammad O. Hoque, Noah M. Hahn, David J. McConkey, Alex S. Baras, Charles G. Drake and Trinity J. BivalacquaCancer Immunol Res July 1 2017 5 (7) 594-603; DOI:10.1158/2326-6066.CIR-16-0267
Intravesical bacillus Calmette–Guéerin (BCG) instillations are standard of care for early stage bladder cancer. BCG was found to recruit T cells to the bladder, but their phenotype was unchanged, implying that combining T cell–activating agents with BCG might improve clinical activity.
- Research ArticlesAlessandra Fragale, Giulia Romagnoli, Valerio Licursi, Maria Buoncervello, Giorgia Del Vecchio, Caterina Giuliani, Stefania Parlato, Celeste Leone, Marta De Angelis, Irene Canini, Elena Toschi, Filippo Belardelli, Rodolfo Negri, Imerio Capone, Carlo Presutti and Lucia GabrieleCancer Immunol Res July 1 2017 5 (7) 604-616; DOI:10.1158/2326-6066.CIR-17-0080
A combination of two epidrugs plus IFN has antitumor effects in colorectal cancer. Epigenetic changes driven by IRF8 in both metastatic colorectal cancer cells and dendritic cells led to increased tumor cell death and increased activity of DCs.
Volume 5, Issue 7